The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

<table>
<thead>
<tr>
<th>Description</th>
<th>Lot # / Exp Date</th>
<th>NDC</th>
<th>UPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>LANSOPRZ DR ODT TB15MG ZYD100@</td>
<td><strong>M915744 10/31/21; M904770 02/28/21;</strong> M005681 03/31/22</td>
<td>68382077177</td>
<td>36838277177</td>
</tr>
<tr>
<td>LANSOPRZ DR ODT TB30MG ZYD100@</td>
<td><strong>M915745 10/31/21; M904772 02/28/21; M900412 12/31/20;</strong> M005682 03/31/22</td>
<td>68382077277</td>
<td>36838277277</td>
</tr>
</tbody>
</table>

Lots in **bold** added to recall.

Zydus is recalling the above items/lots due to an out of specification result observed for dissolution testing. This recall is to the retail level. Affected product started shipping July 5, 2019.